Hemagen Diagnostics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HMGN research report →
About the company
Hemagen Diagnostics, Inc. , a global biotechnology firm, specializes in delivering clinical diagnostic solutions for both human and animal health. The company designs, manufactures, and distributes the VIRGO product line, a series of human clinical immunoassays used for identifying autoimmune and infectious diseases, as well as acute phase proteins.
- CEO
- William Hales
- IPO
- 1993
- Employees
- 15
- HQ
- Columbia, MD, US
Price Chart
- Market Cap
- $40.30K
- P/E
- -0.04
- P/S
- 0.01
- P/B
- -0.01
- EV/EBITDA
- -18.26
- Div Yield
- 0.00%
- Gross Margin
- 39.92%
- Op Margin
- -10.83%
- Net Margin
- -22.45%
- ROE
- 29.06%
- ROIC
- -29.79%
- Revenue
- $4.04M · -21.38%
- Net Income
- $-907,315 · -3.05%
- EPS
- $-0.06 · 2.50%
- Op Income
- $-437,914
- FCF YoY
- -14.26%
- 52W High
- $0.13
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.36
- Avg Volume
- 952
Get TickerSpark's AI analysis on HMGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HMGN coverage
Recent articles, reports, and earnings notes.
No research on HMGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HMGN report →Similar companies
Peers in the same neighborhood.